Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer：a case report

Non-small cell lung cancer（NSCLC） ranks as the leading cause of cancer-related death in the world. Brain metastasis（BM） is a common complication of NSCLC, with 25%–40% of patients developing BM during the course of the disease. A significant strategy of local disease control in the central nervous s...

Full description

Saved in:
Bibliographic Details
Published inCancer biology & medicine Vol. 14; no. 2; pp. 183 - 186
Main Authors Wang, Peng, Xiao, Pei, Ye, Yingnan, Liu, Pengpeng, Han, Lei, Dong, Li, She, Chunhua, Yu, Jinpu
Format Journal Article
LanguageEnglish
Published China Department of Neuro-Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China 01.05.2017
Chinese Anti-Cancer Association
China Anti-Cancer Association
Subjects
Case Report
KLC1-ALK fusion
MET
MET amplification
next-generation sequencing
NSCLC
precision medicine
中枢神经系统
基因扩增
快速反应
患者
放射治疗
阳性
非小细胞肺癌
precision medicine
MET amplification
KLC1-ALK fusion
NSCLC
next-generation sequencing
Online AccessGet full text

Cover

More Information
Summary:Non-small cell lung cancer（NSCLC） ranks as the leading cause of cancer-related death in the world. Brain metastasis（BM） is a common complication of NSCLC, with 25%–40% of patients developing BM during the course of the disease. A significant strategy of local disease control in the central nervous system is radiation therapy. With the development of precision medicine,the concept of treating lung cancer BM has gradually changed. In this case, we performed a surgical procedure to obtain enough tumor tissue for the detection of the target gene and other related experiments after the patient was informed. Finally, we found that the patient had both hepatocyte growth factor receptor（MET） gene amplification and kinesin light chain 1-anaplastic lymphoma kinase fusion（KLC1-ALK） through next-generation sequencing and showed sensitivity to the targeted therapy of crizotinib. The patient exhibited good response. Our case was successful and underwent targeted therapy with the guidance of precise diagnosis.
Bibliography:NSCLC; precision medicine; KLC1-ALK fusion; MET amplification; next-generation sequencing
12-1431/R
Non-small cell lung cancer（NSCLC） ranks as the leading cause of cancer-related death in the world. Brain metastasis（BM） is a common complication of NSCLC, with 25%–40% of patients developing BM during the course of the disease. A significant strategy of local disease control in the central nervous system is radiation therapy. With the development of precision medicine,the concept of treating lung cancer BM has gradually changed. In this case, we performed a surgical procedure to obtain enough tumor tissue for the detection of the target gene and other related experiments after the patient was informed. Finally, we found that the patient had both hepatocyte growth factor receptor（MET） gene amplification and kinesin light chain 1-anaplastic lymphoma kinase fusion（KLC1-ALK） through next-generation sequencing and showed sensitivity to the targeted therapy of crizotinib. The patient exhibited good response. Our case was successful and underwent targeted therapy with the guidance of precise diagnosis.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2095-3941
2095-3941
DOI:10.20892/j.issn.2095-3941.2017.0017